Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse

• DOI: 10.1038/sj.bjc.6605136
• Publication Date: 2009-07-14T20:02:47Z
• Authors: C Kahlert; H Weber; C Mogler; F Bergmann; P Schirmacher; H G Kenngott; U Matterne; N Mollberg; N N Rahbari; U Hinz; M Koch; M Aigner; J Weitz
• Keywords: ALCAM; CA19-9

ALCAM (activated leucocyte cell adhesion molecule, synonym CD166) is a which belongs to the Ig superfamily. Disruption of ALCAM-mediated adhesiveness by proteolytic sheddases such as ADAM17 has been suggested have relevant impact on tumour invasion. Although expression valuable prognostic and predictive marker in several types epithelial tumours, its role pancreatic cancer not yet reported.In this study, paraffin-embedded samples 97 patients with undergoing potentially curative resection were immunostained against ALCAM, CK19. Expression was semiquantitatively evaluated correlated clinical histopathological parameters.We could show that normal tissue, predominantly expressed at cellular membrane, whereas cells, it mainly localised cytoplasm. In addition, univariate multivariate analyses increased an adverse factor for recurrence-free overall survival. Overexpression cancer, however, failed be significant coexpressed ALCAM.Our findings support hypothesis disruption step progression. Moreover, overexpression independent poor survival early relapse cancer.